7 completed, 1 active not recruiting, 1 terminated. 5 Phase 3, 1 Phase 2.
By phase and status
Follow NEAT ID Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
No intervention - Monkeypox, HIV Coinfection | | Completed | NEAT ID Foundation | 2000 | 2023-12-01 | 2025-08-13 |
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 / Phase 3 | Terminated | NEAT ID Foundation | 28 | 2022-10-27 | 2025-05-02 |
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
HIV I Infection | | Active not recruiting | NEAT ID Foundation | 500 | 2022-10-10 | 2026-04-28 |
HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
COVID-19, HIV-1 infection - HIV-1-infection, COVID-19 | | Completed | NEAT ID Foundation | 2598 | 2022-03-29 | 2025-03-24 |
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
Remdesivir - Covid19 | | Completed | NEAT ID Foundation | 451 | 2021-02-12 | 2024-11-29 |
Early Intervention in COVID-19: Favipiravir Verses Standard Care
Favipiravir, Standard of care management - Coronavirus Infection | Phase 3 | Completed | Chelsea and Westminster NHS Foundation Trust | 502 | 2020-05-01 | 2021-11-18 |
The Late Presenter Treatment Optimisation Study
Biktarvy, Symtuza - HIV/AIDS | Phase 3 | Completed | NEAT ID Foundation | 447 | 2019-03-05 | 2025-12-17 |
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy - HIV-1-infection | Phase 3 | Completed | NEAT ID Foundation | 140 | 2018-11-05 | 2024-12-24 |
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Pitavastatin, Placebo - HIV, Cardiovascular Diseases | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 7769 | 2015-03-26 | 2025-09-04 |
Conditions studied
COVID-19 (5) · Coronavirus Infections (2) · Acquired Immunodeficiency Syndrome (1) · Cardiovascular Diseases (1) · HIV Infections (1) · Inflammation (1) · Mpox, Monkeypox (1) · Myocardial Infarction (1)
Interventions
Psychotherapy, Multiple (1) · bictegravir, emtricitabine, tenofovir alafenamide, drug combination (1) · dolutegravir (1) · favipiravir (1) · fostamatinib (1) · pitavastatin (1) · remdesivir (1) · symtuza (1)
Countries
Spain (8) · United Kingdom (7) · France (6) · Belgium (4) · Brazil (3) · Germany (3) · Italy (3) · Netherlands (3) · South Africa (2) · Botswana (1) · Canada (1) · Haiti (1) · India (1) · Ireland (1) · Israel (1)
Top investigators
Anton Pozniak (1) · Anton Pozniak, Prof (1) · Georg Behrens (1) · Nicolo Girometti, MD (1) · Pallav Shah (1) · Steven Grinspoon, MD (1)
Results publications
PMID 28277924, PMID 30928823, PMID 30928825, PMID 32160827, PMID 32645158, PMID 32645159, PMID 32645160, PMID 32645161, PMID 32645162, PMID 32645163, PMID 32645164, PMID 34134131, PMID 34185068, PMID 34794178, PMID 34888395, PMID 35147583, PMID 35165682, PMID 35235653, PMID 35413022, PMID 35535576, PMID 35876637, PMID 35975297, PMID 36101518, PMID 36462699, PMID 36525544, PMID 36528039, PMID 36805331, PMID 36825498, PMID 36966617, PMID 36998633, PMID 37368931, PMID 37439633, PMID 37454762, PMID 37486775, PMID 37503623, PMID 37869406, PMID 38180893, PMID 38197863, PMID 38381407, PMID 38417976, PMID 38533953, PMID 38692296, PMID 39159048, PMID 39253712, PMID 39374532, PMID 39435321, PMID 39661372, PMID 39832519, PMID 40180472, PMID 40207047
NIH funding
2017 (1), U01HL123336 (1), U01HL123339 (1)